# Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

> **NCT01006369** · PHASE2 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 38 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** hydroxychloroquine

## Key facts

- **NCT ID:** NCT01006369
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2015-08-06
- **Final completion:** 2016-04-27
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006369, "Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01006369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*